Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials | Zendy

Michel Sabé | Zendy; Nan Zhao | Zendy; Alessio Crippa | Zendy; Gregory P. Strauss | Zendy; Stefan Kaiser | Zendy

Open Access

Intranasal Oxytocin for Negative Symptoms of Schizophrenia: Systematic Review, Meta-Analysis, and Dose-Response Meta-Analysis of Randomized Controlled Trials

Author(s) -

Michel Sabé,

Nan Zhao,

Alessio Crippa,

Gregory P. Strauss,

Stefan Kaiser

Publication year - 2021

Publication title -

the international journal of neuropsychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 107

eISSN - 1469-5111

pISSN - 1461-1457

DOI - 10.1093/ijnp/pyab020

Subject(s) - oxytocin , meta analysis , medicine , randomized controlled trial , placebo , nasal administration , schizophrenia (object oriented programming) , strictly standardized mean difference , therapeutic effect , pharmacology , psychiatry , alternative medicine , pathology

Negative symptoms are a core aspect of psychopathology in schizophrenia. Currently available pharmacological agents have proven minimally efficacious for remediating negative symptoms. A promising treatment avenue is the intranasal administration of the neuropeptide oxytocin. However, there have been inconsistencies in effects of oxytocin on negative symptoms throughout the literature, and factors leading to inconsistent effects are unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research